Brad Ebanks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brad Ebanks has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Lisa Chakrabarti
School of Veterinary Medicine and Science, University of Nottingham, Nottingham, United Kingdom
3 shared publications Lisa Chakrabarti
School of Veterinary Medicine and Science, University of Nottingham, Nottingham, United Kingdom
2 shared publications- Nicoleta Moisoi
Leicester School of Pharmacy, Leicester Institute for Pharmaceutical Innovation, De Montfort University, The Gateway, Leicester LE1 9BH, UK
2 shared publications Adam Brookfield
1 shared publication- Adam Dowle
University of York
1 shared publication Chiara Papetti
Biology Department, University of Padova, Padova, Italy
1 shared publication
Latest Publications
- Open Access
Detecting Mitochondrial Free Radicals with Quantum Sensors: From Organelles to a D. melanogaster Model of Neurodegeneration
This study identifies a distinct free radical signature in a D. melanogaster model of Parkinson’s Disease, successfully differentiating Pink1-deficient flies from wild-type controls. This insight was achieved using a robust quantum sensing methodology for the selective detection of free radicals in biological systems. Our approach utilizes optically detected magnetic resonance (ODMR) and magnetic modulation (MM) protocols with nanodiamond nitrogen-vacancy (NV) centres. Selective identification is achieved using the spin probe TEMPOL, a cell-permeable superoxide dismutase 2 (SOD2) mimic that initially quenches the photoluminescence signal. Upon scavenging free radicals like hydroxyl and superoxide, TEMPOL is converted to a diamagnetic adduct, restoring the contrast and thus enabling quantitative detection. The approach was first validated in a chemical system with radical generation confirmed by electron paramagnetic resonance (EPR) spectroscopy. It was then demonstrated across biological scales, from isolated mitochondria and whole glioblastoma cells to the Drosophila model. In these studies, high-resolution respirometry revealed distinct free radical signatures, and findings were compared with NV T1 relaxometry. This work provides new biophysical insight into mitochondrial dysfunction, demonstrating a distinct free radical signature in a neurodegeneration model and connecting it to specific metabolic states.
Open AccessDetecting Mitochondrial Free Radicals with Quantum Sensors: From Organelles to a D. melanogaster Model of Neurodegeneration
This study identifies a distinct free radical signature in a D. melanogaster model of Parkinson’s Disease, successfully differentiating Pink1-deficient flies from wild-type controls. This insight was achieved using a robust quantum sensing methodology for the selective detection of free radicals in biological systems. Our approach utilizes optically detected magnetic resonance (ODMR) and magnetic modulation (MM) protocols with nanodiamond nitrogen-vacancy (NV) centres. Selective identification is achieved using the spin probe TEMPOL, a cell-permeable superoxide dismutase 2 (SOD2) mimic that initially quenches the photoluminescence signal. Upon scavenging free radicals like hydroxyl and superoxide, TEMPOL is converted to a diamagnetic adduct, restoring the contrast and thus enabling quantitative detection. The approach was first validated in a chemical system with radical generation confirmed by electron paramagnetic resonance (EPR) spectroscopy. It was then demonstrated across biological scales, from isolated mitochondria and whole glioblastoma cells to the Drosophila model. In these studies, high-resolution respirometry revealed distinct free radical signatures, and findings were compared with NV T1 relaxometry. This work provides new biophysical insight into mitochondrial dysfunction, demonstrating a distinct free radical signature in a neurodegeneration model and connecting it to specific metabolic states.
- Open Access
Mitochondrial Haemoglobin Is Upregulated with Hypoxia in Skeletal Muscle and Has a Conserved Interaction with ATP Synthase and Inhibitory Factor 1
The globin protein superfamily has diverse functions. Haemoglobin has been found in non-erythroid locations, including within the mitochondria. Using co-immunoprecipitation and in silico methods, we investigated the interaction of mitochondrial haemoglobin with ATP synthase and its associated proteins, including inhibitory factor 1 (IF1). We measured the expression of mitochondrial haemoglobin in response to hypoxia. In vitro and in silico evidence of interactions between mitochondrial haemoglobin and ATP synthase were found, and we report upregulated mitochondrial haemoglobin expression in response to hypoxia within skeletal muscle tissue. Our observations indicate that mitochondrial pH and ATP synthase activity are implicated in the mitochondrial haemoglobin response to hypoxia.
Open AccessMitochondrial Haemoglobin Is Upregulated with Hypoxia in Skeletal Muscle and Has a Conserved Interaction with ATP Synthase and Inhibitory Factor 1
The globin protein superfamily has diverse functions. Haemoglobin has been found in non-erythroid locations, including within the mitochondria. Using co-immunoprecipitation and in silico methods, we investigated the interaction of mitochondrial haemoglobin with ATP synthase and its associated proteins, including inhibitory factor 1 (IF1). We measured the expression of mitochondrial haemoglobin in response to hypoxia. In vitro and in silico evidence of interactions between mitochondrial haemoglobin and ATP synthase were found, and we report upregulated mitochondrial haemoglobin expression in response to hypoxia within skeletal muscle tissue. Our observations indicate that mitochondrial pH and ATP synthase activity are implicated in the mitochondrial haemoglobin response to hypoxia.
- 1 August 2022
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 323 (2) , R181-R192
Proteomic analysis of the ATP synthase interactome in notothenioids highlights a pathway that inhibits ceruloplasmin production
Antarctic notothenioids have unique adaptations that allow them to thrive in subzero Antarctic waters. Within the suborder Notothenioidei, species of the family Channichthyidae (icefish) lack hemoglobin and in some instances myoglobin too. In studies of mitochondrial function of notothenioids, few have focused specifically on ATP synthase. In this study, we find that the icefish Champsocephalus gunnari has a significantly higher level of ATP synthase subunit α expression than the red-blooded Notothenia rossii, but a much smaller interactome than the other species. We characterize the interactome of ATP synthase subunit α in two red-blooded species Trematomus bernacchii, N. rossii, and in the icefish Chionodraco rastrospinosus and C. gunnari and find that, in comparison with the other species, reactome enrichment for C. gunnari lacks chaperonin-mediated protein folding, and fewer oxidative-stress-associated proteins are present in the identified interactome of C. gunnari. Reactome enrichment analysis also identifies a transcript-specific translational silencing pathway for the iron oxidase protein ceruloplasmin, which has previously been reported in studies of icefish as distinct from other red-blooded fish and vertebrates in its activity and RNA transcript expression. Ceruloplasmin protein expression is detected by Western blot in the liver of T. bernacchii, but not in N. rossii, C. rastrospinosus, and C. gunnari. We suggest that the translation of ceruloplasmin transcripts is silenced by the identified pathway in icefish notothenioids, which is indicative of altered iron metabolism and Fe(II) detoxification.
- 1 August 2022
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 323 (2) , R181-R192
Proteomic analysis of the ATP synthase interactome in notothenioids highlights a pathway that inhibits ceruloplasmin production
Antarctic notothenioids have unique adaptations that allow them to thrive in subzero Antarctic waters. Within the suborder Notothenioidei, species of the family Channichthyidae (icefish) lack hemoglobin and in some instances myoglobin too. In studies of mitochondrial function of notothenioids, few have focused specifically on ATP synthase. In this study, we find that the icefish Champsocephalus gunnari has a significantly higher level of ATP synthase subunit α expression than the red-blooded Notothenia rossii, but a much smaller interactome than the other species. We characterize the interactome of ATP synthase subunit α in two red-blooded species Trematomus bernacchii, N. rossii, and in the icefish Chionodraco rastrospinosus and C. gunnari and find that, in comparison with the other species, reactome enrichment for C. gunnari lacks chaperonin-mediated protein folding, and fewer oxidative-stress-associated proteins are present in the identified interactome of C. gunnari. Reactome enrichment analysis also identifies a transcript-specific translational silencing pathway for the iron oxidase protein ceruloplasmin, which has previously been reported in studies of icefish as distinct from other red-blooded fish and vertebrates in its activity and RNA transcript expression. Ceruloplasmin protein expression is detected by Western blot in the liver of T. bernacchii, but not in N. rossii, C. rastrospinosus, and C. gunnari. We suggest that the translation of ceruloplasmin transcripts is silenced by the identified pathway in icefish notothenioids, which is indicative of altered iron metabolism and Fe(II) detoxification.
- Open Access
- 14 February 2022
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 9, 854321
Mitochondrial ATP Synthase is a Target of Oxidative Stress in Neurodegenerative Diseases
The mitochondrial ATP synthase is responsible for the production of cellular ATP, and it does so by harnessing the membrane potential of the mitochondria that is produced by the sequential oxidation of select cellular metabolites. Since the structural features of ATP synthase were first resolved nearly three decades ago, significant progress has been made in understanding its role in health and disease. Mitochondrial dysfunction is common to neurodegeneration, with elevated oxidative stress a hallmark of this dysfunction. The patterns of this oxidative stress, including molecular targets and the form of oxidative modification, can vary widely. In this mini review we discuss the oxidative modifications of ATP synthase that have been observed in Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. Oxidative modifications of ATP synthase in Alzheimer’s disease are well-documented, and there is a growing body of knowledge on the subject in Parkinson’s disease. The consideration of ATP synthase as a pharmacological target in a variety of diseases underlines the importance of understanding these modifications, both as a potential target, and also as inhibitors of any pharmacological intervention.
- 14 February 2022
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 9, 854321
Open AccessMitochondrial ATP Synthase is a Target of Oxidative Stress in Neurodegenerative Diseases
The mitochondrial ATP synthase is responsible for the production of cellular ATP, and it does so by harnessing the membrane potential of the mitochondria that is produced by the sequential oxidation of select cellular metabolites. Since the structural features of ATP synthase were first resolved nearly three decades ago, significant progress has been made in understanding its role in health and disease. Mitochondrial dysfunction is common to neurodegeneration, with elevated oxidative stress a hallmark of this dysfunction. The patterns of this oxidative stress, including molecular targets and the form of oxidative modification, can vary widely. In this mini review we discuss the oxidative modifications of ATP synthase that have been observed in Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. Oxidative modifications of ATP synthase in Alzheimer’s disease are well-documented, and there is a growing body of knowledge on the subject in Parkinson’s disease. The consideration of ATP synthase as a pharmacological target in a variety of diseases underlines the importance of understanding these modifications, both as a potential target, and also as inhibitors of any pharmacological intervention.
- Open Access
- 27 August 2020
- Published by Impact Journals, LLC in Aging
- Vol. 12 (16) , 16647-16662
ATP synthase and Alzheimer’s disease: putting a spin on the mitochondrial hypothesis
It is estimated that over 44 million people across the globe have dementia, and half of these cases are believed to be Alzheimer’s disease (AD). As the proportion of the global population which is over the age 60 increases so will the number of individuals living with AD. This will result in ever-increasing demands on healthcare systems and the economy. AD can be either sporadic or familial, but both present with similar pathobiology and symptoms. Three prominent theories about the cause of AD are the amyloid, tau and mitochondrial hypotheses. The mitochondrial hypothesis focuses on mitochondrial dysfunction in AD, however little attention has been given to the potential dysfunction of the mitochondrial ATP synthase in AD. ATP synthase is a proton pump which harnesses the chemical potential energy of the proton gradient across the inner mitochondrial membrane (IMM), generated by the electron transport chain (ETC), in order to produce the cellular energy currency ATP. This review presents the evidence accumulated so far that demonstrates dysfunction of ATP synthase in AD, before highlighting two potential pharmacological interventions which may modulate ATP synthase.
- 27 August 2020
- Published by Impact Journals, LLC in Aging
- Vol. 12 (16) , 16647-16662
Open AccessATP synthase and Alzheimer’s disease: putting a spin on the mitochondrial hypothesis
It is estimated that over 44 million people across the globe have dementia, and half of these cases are believed to be Alzheimer’s disease (AD). As the proportion of the global population which is over the age 60 increases so will the number of individuals living with AD. This will result in ever-increasing demands on healthcare systems and the economy. AD can be either sporadic or familial, but both present with similar pathobiology and symptoms. Three prominent theories about the cause of AD are the amyloid, tau and mitochondrial hypotheses. The mitochondrial hypothesis focuses on mitochondrial dysfunction in AD, however little attention has been given to the potential dysfunction of the mitochondrial ATP synthase in AD. ATP synthase is a proton pump which harnesses the chemical potential energy of the proton gradient across the inner mitochondrial membrane (IMM), generated by the electron transport chain (ETC), in order to produce the cellular energy currency ATP. This review presents the evidence accumulated so far that demonstrates dysfunction of ATP synthase in AD, before highlighting two potential pharmacological interventions which may modulate ATP synthase.